Glaxo under pressure on 'danger' drug

[Guest guest]

http://www.thisislondon.co.uk/news/business/articles/timid79278?source=

Glaxo under pressure on 'danger' drug

Bill Condie, Evening Standard

11 June 2004

INFLUENTIAL medical journal the Lancet has joined the growing furore over

GlaxoKline's antidepressant drug Seroxat by criticising the way the

pharmaceuticals giant has published research on the treatment.

Seroxat is at the centre of a lawsuit brought against the company by New York

Attorney General Eliot Spitzer, who alleges it suppressed the results of

research that showed the treatment may have been dangerous for under 18s.

Spitzer is seeking at least $300m (£163m) from Glaxo, which is headed by

Jean-Pierre Garnier.

The Lancet, meanwhile, said: 'If GSK has nothing to hide, as it claims, it

should open the files before being ordered to do so by a court - and do so right

now.'

The drug, marketed in the US as Paxil, has been the subject of controversy on

both sides of the Atlantic because of a possible increased risk of suicidal

behaviour in young patients.

The Lancet, the medical journal of the British Medical Association, said the

company had sponsored at least five studies that tested the drug's efficacy in

children but only one, which had mixed results, had been published.

It added that even those results had only been released to the Food and Drug

Administration in the US and other regulatory agencies. Doctors and consumers

also needed the information to make informed decisions, it said.

Glaxo denies the allegations, and last night released summaries of nine studies

it had conducted into the treatment.

Many researchers and journals have argued that all clinical trials should be

registered and all results published. 'As the lawsuit pointedly demonstrates,

the time has come for these matters to be revealed in a bright and public

light,' the Lancet said.

Spitzer is demanding that Glaxo give up all profits from the sale of the drug in

New York for treating depression in children and teens. He is also seeking

unspecified damages.

Glaxo is also facing legal action in Australia, where biotech company Biota

claims it failed to properly promote flu drug Relenza, which it had licensed

from the Australian company. Biota said Glaxo had caused sales to crash.

Glaxo would not comment but is required to file a defence to the claim. There

will be a hearing on 18 June.

©2004 Associated New Media | Terms | Privacy policy

[Guest guest]

http://www.thisislondon.co.uk/news/business/articles/timid79278?source=

Glaxo under pressure on 'danger' drug

Bill Condie, Evening Standard

11 June 2004

INFLUENTIAL medical journal the Lancet has joined the growing furore over

GlaxoKline's antidepressant drug Seroxat by criticising the way the

pharmaceuticals giant has published research on the treatment.

Seroxat is at the centre of a lawsuit brought against the company by New York

Attorney General Eliot Spitzer, who alleges it suppressed the results of

research that showed the treatment may have been dangerous for under 18s.

Spitzer is seeking at least $300m (£163m) from Glaxo, which is headed by

Jean-Pierre Garnier.

The Lancet, meanwhile, said: 'If GSK has nothing to hide, as it claims, it

should open the files before being ordered to do so by a court - and do so right

now.'

The drug, marketed in the US as Paxil, has been the subject of controversy on

both sides of the Atlantic because of a possible increased risk of suicidal

behaviour in young patients.

The Lancet, the medical journal of the British Medical Association, said the

company had sponsored at least five studies that tested the drug's efficacy in

children but only one, which had mixed results, had been published.

It added that even those results had only been released to the Food and Drug

Administration in the US and other regulatory agencies. Doctors and consumers

also needed the information to make informed decisions, it said.

Glaxo denies the allegations, and last night released summaries of nine studies

it had conducted into the treatment.

Many researchers and journals have argued that all clinical trials should be

registered and all results published. 'As the lawsuit pointedly demonstrates,

the time has come for these matters to be revealed in a bright and public

light,' the Lancet said.

Spitzer is demanding that Glaxo give up all profits from the sale of the drug in

New York for treating depression in children and teens. He is also seeking

unspecified damages.

Glaxo is also facing legal action in Australia, where biotech company Biota

claims it failed to properly promote flu drug Relenza, which it had licensed

from the Australian company. Biota said Glaxo had caused sales to crash.

Glaxo would not comment but is required to file a defence to the claim. There

will be a hearing on 18 June.

©2004 Associated New Media | Terms | Privacy policy

[Guest guest]

http://www.thisislondon.co.uk/news/business/articles/timid79278?source=

Glaxo under pressure on 'danger' drug

Bill Condie, Evening Standard

11 June 2004

INFLUENTIAL medical journal the Lancet has joined the growing furore over

GlaxoKline's antidepressant drug Seroxat by criticising the way the

pharmaceuticals giant has published research on the treatment.

Seroxat is at the centre of a lawsuit brought against the company by New York

Attorney General Eliot Spitzer, who alleges it suppressed the results of

research that showed the treatment may have been dangerous for under 18s.

Spitzer is seeking at least $300m (£163m) from Glaxo, which is headed by

Jean-Pierre Garnier.

The Lancet, meanwhile, said: 'If GSK has nothing to hide, as it claims, it

should open the files before being ordered to do so by a court - and do so right

now.'

The drug, marketed in the US as Paxil, has been the subject of controversy on

both sides of the Atlantic because of a possible increased risk of suicidal

behaviour in young patients.

The Lancet, the medical journal of the British Medical Association, said the

company had sponsored at least five studies that tested the drug's efficacy in

children but only one, which had mixed results, had been published.

It added that even those results had only been released to the Food and Drug

Administration in the US and other regulatory agencies. Doctors and consumers

also needed the information to make informed decisions, it said.

Glaxo denies the allegations, and last night released summaries of nine studies

it had conducted into the treatment.

Many researchers and journals have argued that all clinical trials should be

registered and all results published. 'As the lawsuit pointedly demonstrates,

the time has come for these matters to be revealed in a bright and public

light,' the Lancet said.

Spitzer is demanding that Glaxo give up all profits from the sale of the drug in

New York for treating depression in children and teens. He is also seeking

unspecified damages.

Glaxo is also facing legal action in Australia, where biotech company Biota

claims it failed to properly promote flu drug Relenza, which it had licensed

from the Australian company. Biota said Glaxo had caused sales to crash.

Glaxo would not comment but is required to file a defence to the claim. There

will be a hearing on 18 June.

©2004 Associated New Media | Terms | Privacy policy

[Guest guest]

http://www.thisislondon.co.uk/news/business/articles/timid79278?source=

Glaxo under pressure on 'danger' drug

Bill Condie, Evening Standard

11 June 2004

INFLUENTIAL medical journal the Lancet has joined the growing furore over

GlaxoKline's antidepressant drug Seroxat by criticising the way the

pharmaceuticals giant has published research on the treatment.

Seroxat is at the centre of a lawsuit brought against the company by New York

Attorney General Eliot Spitzer, who alleges it suppressed the results of

research that showed the treatment may have been dangerous for under 18s.

Spitzer is seeking at least $300m (£163m) from Glaxo, which is headed by

Jean-Pierre Garnier.

The Lancet, meanwhile, said: 'If GSK has nothing to hide, as it claims, it

should open the files before being ordered to do so by a court - and do so right

now.'

The drug, marketed in the US as Paxil, has been the subject of controversy on

both sides of the Atlantic because of a possible increased risk of suicidal

behaviour in young patients.

The Lancet, the medical journal of the British Medical Association, said the

company had sponsored at least five studies that tested the drug's efficacy in

children but only one, which had mixed results, had been published.

It added that even those results had only been released to the Food and Drug

Administration in the US and other regulatory agencies. Doctors and consumers

also needed the information to make informed decisions, it said.

Glaxo denies the allegations, and last night released summaries of nine studies

it had conducted into the treatment.

Many researchers and journals have argued that all clinical trials should be

registered and all results published. 'As the lawsuit pointedly demonstrates,

the time has come for these matters to be revealed in a bright and public

light,' the Lancet said.

Spitzer is demanding that Glaxo give up all profits from the sale of the drug in

New York for treating depression in children and teens. He is also seeking

unspecified damages.

Glaxo is also facing legal action in Australia, where biotech company Biota

claims it failed to properly promote flu drug Relenza, which it had licensed

from the Australian company. Biota said Glaxo had caused sales to crash.

Glaxo would not comment but is required to file a defence to the claim. There

will be a hearing on 18 June.

©2004 Associated New Media | Terms | Privacy policy